6P62 image
Deposition Date 2019-05-31
Release Date 2019-11-20
Last Version Date 2024-10-23
Entry Detail
PDB ID:
6P62
Title:
HIV Env BG505 NFL TD+ in complex with antibody E70 fragment antigen binding
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.57 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:HIV-1 Env BG505 NFL TD+
Chain IDs:A, D (auth: B), G (auth: E)
Chain Length:675
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Molecule:Rabbit monoclonal antibody E70 heavy chain fragment antigen binding
Chain IDs:B (auth: H), E (auth: C), H (auth: F)
Chain Length:224
Number of Molecules:3
Biological Source:Oryctolagus cuniculus
Polymer Type:polypeptide(L)
Molecule:Rabbit monoclonal antibody E70 kappa chain
Chain IDs:C (auth: L), F (auth: D), I (auth: G)
Chain Length:213
Number of Molecules:3
Biological Source:Oryctolagus cuniculus
Primary Citation
Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability.
Immunity 51 915 929.e7 (2019)
PMID: 31732167 DOI: 10.1016/j.immuni.2019.10.008

Abstact

The elicitation of broadly neutralizing antibodies (bNAbs) against the HIV-1 envelope glycoprotein (Env) trimer remains a major vaccine challenge. Most cross-conserved protein determinants are occluded by self-N-glycan shielding, limiting B cell recognition of the underlying polypeptide surface. The exceptions to the contiguous glycan shield include the conserved receptor CD4 binding site (CD4bs) and glycoprotein (gp)41 elements proximal to the furin cleavage site. Accordingly, we performed heterologous trimer-liposome prime:boosting in rabbits to drive B cells specific for cross-conserved sites. To preferentially expose the CD4bs to B cells, we eliminated proximal N-glycans while maintaining the native-like state of the cleavage-independent NFL trimers, followed by gradual N-glycan restoration coupled with heterologous boosting. This approach successfully elicited CD4bs-directed, cross-neutralizing Abs, including one targeting a unique glycan-protein epitope and a bNAb (87% breadth) directed to the gp120:gp41 interface, both resolved by high-resolution cryoelectron microscopy. This study provides proof-of-principle immunogenicity toward eliciting bNAbs by vaccination.

Legend

Protein

Chemical

Disease

Primary Citation of related structures